Systemic delivery of decorin to prostate-specific Pten(P−/−) mice, a genetically defined, immune-competent mouse model of prostate cancer, inhibits tumour progression by targeting cell proliferation and survival pathways [9]. Here, DCN is linked to prostate carcinoma.